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Abstract
Aims Octogenarians have the highest incidence of heart failure (HF) that is not fully explained by traditional risk factors. We
explored whether lack of pneumococcal vaccination is associated with higher risk of incident HF among octogenarians.
Methods and results In the Cardiovascular Health Study (CHS), 5290 community-dwelling adults, ≥65 years of age, were free
of baseline HF and had data on pneumococcal vaccination. Of these, 851 were octogenarians, of whom, 593 did not receive
pneumococcal vaccination. Multivariable-adjusted hazard ratios (aHR) and 95% confidence intervals (CI) for associations of
lack of pneumococcal vaccination with incident HF and other outcomes during 13 years of follow-up were estimated using
Cox regression models, adjusting for demographics and other HF risk factors including influenza vaccination. Octogenarians
had a mean (±SD) age of 83 (±3) years; 52% were women and 17% African American. Overall, 258 participants developed
HF and 662 died. Lack of pneumococcal vaccination was associated with higher relative risk of incident HF (aHR, 1.37; 95%
CI, 1.01–1.85; P = 0.044). There was also higher risk for all-cause mortality (aHR, 1.23; 95% CI, 1.02–1.49; P = 0.028), which
was mostly driven by cardiovascular mortality (aHR, 1.45; 95% CI, 1.06–1.98; P = 0.019). Octogenarians without pneumococcal
vaccination had a trend toward higher risk of hospitalization due to pneumonia (aHR, 1.34; 95% CI, 0.99–1.81; P = 0.059).
These associations were not observed among those 65–79 years of age.
Conclusions Among community-dwelling octogenarians, lack of pneumococcal vaccination was associated with a signifi-
cantly higher independent risk of incident HF and mortality, and trend for higher pneumonia hospitalization.
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Octogenarians are among the fastest growing segments of
the US population, and they also have the highest
incidence of heart failure (HF).1–3 However, traditional risk
factors for incident HF do not appear to explain this
incidence as their impact appears to attenuate with
ageing.4–7 For example, in the Cardiovascular Health Study
(CHS), among those <78 years of age, 18% and 13% of
those with and without isolated systolic hypertension
(ISH) developed new HF, respectively, which corresponded
with a 44% higher relative risk for those with ISH.4 In
contrast, among those ≥78 years of age, 24% and 25%
of those with and without ISH developed new HF.
Similarly, isolated diastolic hypertension was associated
with a 33% significantly higher independent risk of
incident HF, which was only observed among those
<75 years of age.5
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Thus, there is a need to identify non-traditional risk factors
for incident HF among the oldest old who have the highest
incidence of HF that is not well explained by traditional risk
factors. In this context, we conducted an exploratory analysis
to determine if lack of pneumococcal vaccination is associ-
ated with higher risk of incident HF. Although pneumococcal
infection is a major cause of cardiovascular morbidity,8 it
has been suggested that pneumococcal vaccination may
reduce the risk of cardiovascular events.9,10 Therefore, in
the current study, we examined whether lack of pneumococ-
cal vaccination is associated with higher risk of incident HF in
community-dwelling octogenarians.
Methods
Data source and study participants
We used de-identified copies of the CHS data obtained from
the National Heart, Lung and Blood Institute (NHLBI), which
also sponsored the study. The rationale and design of the
CHS have been previously reported.11 The CHS is an ongoing,
prospective, community-based epidemiologic study based
on 5888 Medicare-eligible community-dwelling older
adults, aged 65 year and older, from Forsyth County, North
Carolina; Sacramento County, California; Washington County,
Maryland; and Pittsburgh, Pennsylvania. An initial cohort of
5201 participants was recruited between 1989 and 1990,
and a second cohort of 687 African Americans was recruited
between 1992 and 1993. Of the 5888 CHS participants, 5795
consent to be included in the public-use copy of the data.
Of these, 240 without data on baseline pneumococcal vacci-
nation and 265 with baseline prevalent HF were excluded.
Of the remaining 5290, 851 were 80 years and older and
4439 were 65 to 79 years of age at baseline. Data on pneu-
mococcal vaccination were collected at baseline by asking
the questions: ‘Have you ever had a shot to prevent
pneumonia (pneumovax)?’12 Additional data on socio-
demographic characteristics, health behaviours, self-rated
health and vaccination history, comorbid conditions, medi-
cations, vital signs, markers of inflammation, and other bio-
chemical covariates were collected at baseline and have been
previously described in details.11 Missing values for variables
were imputed based on values predicted by age, sex, and race.
Outcomes
Primary outcomes for the current analysis were incident
HF and all-cause mortality during 13 years of follow-up.
Incident HF was centrally adjudicated by the CHS Events
Committee, which has been well described in literature.13
The process began with self-reports of physician-diagnosed
HF, which were then confirmed by review of medical records
for symptoms, signs, medications, and other evidence of HF.4–7
The CHS criteria for HF diagnosis have been shown to be more
stringent than those used in the Framingham Heart Study.14
Secondary outcomes of interest were cardiovascular and
non-cardiovascular mortality, as well as all-cause hospitaliza-
tion and hospitalization due to pneumonia.
Statistical analysis
For descriptive analyses, we used Pearson’s χ2 for categorical
variables and analysis of variance for continuous variables.
Kaplan Meier survival analysis was used to determine the as-
sociation of pneumococcal vaccination with outcomes during
13 years of follow-up. Unadjusted and multivariable-adjusted
Cox regression models were used to estimate the association
of lack of pneumococcal vaccination with outcomes. All sta-
tistical tests were two-sided, and tests with P-value <0.05
were considered significant. SPSS for Windows (Version 18)
was used for data analysis. We repeated our analysis in
participants 65 to 79 years of age.
Results
Baseline characteristics
Octogenarians had a mean (±SD) age of 83 (±3) years;
52% were female, and 17% were African American. The
distribution of baseline characteristics between partici-
pants receiving or not receiving pneumococcal vaccination
was generally balanced (Table 1). A greater proportion of
octogenarians receiving pneumococcal vaccination also
received influenza vaccination and had higher prevalence
of chronic obstructive pulmonary disease and pneumonia.
Incident heart failure
During 13 years of follow-up, among octogenarians, a
non-receipt of pneumococcal vaccination at baseline was
associated with significantly higher risk of incident HF
[adjusted hazard ratio (aHR), 1.37; 95% confidence interval
(CI), 1.01–1.85; Figure 1 and Table 2). In contrast, among
those 65–79 years, a non-use of pneumococcal vaccination
was not associated with incident HF (aHR, 0.88; 95% CI,
0.74–1.04; Table 2).
Mortality
Compared with octogenarians who received pneumococcal
vaccination, non-receipt of pneumococcal vaccination was
associated with significantly higher risk of all-cause mortality
12 A. Ahmed et al.
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(aHR, 1.23; 95% CI, 1.02–1.49), CV mortality (aHR, 1.45; 95%
CI, 1.06–1.98), but not of non-CV mortality (aHR, 1.10; 95%
CI, 0.87–1.40; Table 2). Pneumococcal vaccination had no asso-
ciation with mortality among those 65–79years of age (Table 3).
Hospitalization
Among octogenarians, non-receipt of pneumococcal vaccina-
tion had no association with all-cause hospitalization (aHR,
1.04; 95% CI, 0.87–1.40), but there was a trend toward higher
risk of hospitalization due to pneumonia (aHR, 1.35; 95% CI,
1.00–1.82; Table 2). None of these associations were signifi-
cant among those 65–79 years of age(Table 3).
Discussion
Findings from the current study demonstrated that among
community-dwelling octogenarians, the lack of a prior
pneumococcal vaccination was associated with higher risk
of incident HF and cardiovascular mortality. We also
observed that there was a trend toward higher risk of
hospitalization due to pneumonia. Lack of pneumococcal
vaccination, however, had no association with these out-
comes among older adults 65 to 79 years of age. These
findings are hypothesis generating and suggest that pneu-
mococcal infections may be a non-traditional risk factor
for incident HF among octogenarians, and that pneumo-
coccal vaccination may lower the risk of HF among
octogenarians.
The association of lack of pneumococcal vaccination and
higher incident HF is unlikely to be confounded by other ma-
jor HF risk factors such as prior myocardial infraction, hyper-
tension, diabetes, and left ventricular systolic dysfunction as
they were similarly distributed at baseline between octoge-
narians with and without prior pneumococcal vaccination
and we adjusted for those in our multivariable model. They
are also unlikely to be explained by chronic obstructive pul-
monary disease and pneumonia as fewer octogenarians not
receiving pneumococcal vaccination had these conditions,
likely explained by the fact that they were potential indica-
tions for pneumococcal vaccination.12 Findings from animal
studies suggest that human C-reactive protein (CRP) may pro-
tect mice from pneumococcal infection15 and pneumococcal
vaccination is often associated with higher CRP levels.16 Octo-
genarians without a prior pneumococcal vaccination had
higher CRP levels, and although adjusted for in our multivar-
iable model, residual bias is possible. Influenza vaccination
has been shown to be associated with lower cardiovascu-
lar events.17–20 Octogenarians without pneumococcal vacci-
nation were less likely to receive influenza vaccination.
Although this was adjusted for, residual bias is possible.
It is also possible that lack of vaccination was a marker
of less healthy life style for octogenarians with no prior
vaccination, which may have contributed to their poor car-
diovascular outcomes. However, there was no difference in
Figure 1 Multivariable-adjusted risk for incident heart failure among Car-
diovascular Health Study participants aged 80 years or older (Hazard ratio



















Hazard ratio = 1.37;
95% CI = 1.01–1.85;
P = 0.044
Table 2 Association of lack of pneumococcal vaccination with outcomes in octogenarians in the CHS
Events (%)
Hazard ratio* (95% confidence interval); P-valuePneumococcal vaccination
No (n=593) Yes (n=258) Unadjusted Multivariable-adjusted†
Incident heart failure 183 (31%) 75 (29%) 1.21 (0.92–1.58); P=0.165 1.37 (1.01–1.85); P=0.044
All-cause mortality 474 (80%) 188 (73%) 1.29 (1.09–1.53); P=0.003 1.23 (1.02–1.49); P=0.028
Cardiovascular 201 (34%) 68 (26%) 1.50 (1.14–1.98); P=0.004 1.45 (1.06–1.98); P=0.019
Non-cardiovascular 272 (46%) 120 (47%) 1.16 (0.94–1.44); P=0.168 1.10 (0.87–1.40); P=0.426
All-cause hospitalization 530 (89%) 236 (92%) 1.01 (0.87–1.18); P=0.919 1.04 (0.87–1.24); P=0.643
Pneumonia 184 (31%) 75 (29%) 1.20 (0.92–1.57); P=0.183 1.35 (1.00–1.82); P=0.051
CHS, Cardiovascular Health Study.
*Hazard ratio, when non-use of pneumococcal vaccination was compared with their use.
†Adjusted for age ≥85 years, sex, race, married, education college or higher, income ≥$25K, smoking ≥32 pack-years, walk blocks last week
≥10, body mass index ≥25 kg/m2, instrumental activities of daily living ≥1, Centers for Epidemiologic Studies Depression (CES-D) scale
score, Mini-mental state examination (30 item), influenza vaccination, coronary heart diseases, hypertension, diabetes, stroke, acute
myocardial infarction, atrial fibrillation, left ventricular hypertrophy, left ventricular systolic dysfunction, left bundle branch block, chronic
kidney disease, chronic obstructive pulmonary disease, pneumonia, serum C-reactive protein ≥2.4mg/L.
14 A. Ahmed et al.
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other markers of healthy life style such body mass index
between the two groups suggesting a healthy life style
cannot fully explain our findings.
We used very similar risk-adjustment models for both oc-
togenarians and those 65–79 years of age. Further,
between-group prevalence of major HF, risk factors were
also similar for both octogenarians and those 65–79 years
of age. Yet, despite a larger sample size and higher number
of events in those 65–79 years of age, pneumococcal vacci-
nation had no association with incident HF or mortality. This
may suggest that the associations observed among the oc-
togenarians are due to chance. However, prior studies have
reported that pneumococcal vaccination to be associated
with better CV outcomes.9,10 In one study, the use of pneu-
mococcal vaccination was associated with higher risk of CV
outcomes among those <65 years of age, while there was
no such association among those ≥65 years of age.21,22
Taken together with the findings from our study, these find-
ings suggest that there might exist a potential age-related
variation in the benefit of pneumococcal vaccination. Oxi-
dized low-density lipoproteins play an important role in ath-
erogenesis, and antibodies against them may cause
regression of atherosclerosis.23,24 In laboratory animals,
pneumococcal vaccination has been shown to decrease ath-
erosclerotic lesion.25 Preliminary findings from human stud-
ies suggest that pneumococcal vaccination may induce
antibodies against oxidized low-density lipoproteins.26 Al-
though oxidized low-density lipoproteins are not known HF
risk factors, they have been shown to be associated with
other cardiovascular events.27
Pneumococcal disease is common among older adults, spe-
cifically among octogenarians,28,29 and pneumococcal vacci-
nation is recommended for all adults ≥65 years of age.30
Findings from the current study suggest that this vaccination
might also lower the risk of HF and CV mortality among octo-
genarians. Prospective studies of pneumococcal vaccination in
octogenarians would be unethical as it would require delaying
vaccination until that age. However, if these findings can be
replicated in other octogenarian populations, this might pro-
vide an inexpensive tool for improving the health and out-
comes of the fastest growing segment of the US population.
It will also provide additional rationale to increase the utiliza-
tion of pneumococcal vaccination, which remains low, about
60% among adults ≥65 years of age in 2010.8
Our study has several limitations. As discussed earlier, an
important limitation of any observational study is the poten-
tial for bias due to unmeasured confounders, and ours is no
exception. We had no data on the time of pneumococcal vac-
cination. The 23-valent polysaccharide pneumococcal vaccine
was licenced in 1977 and has been reimbursed by Medicare
since 1981.31,32 Although utilization of pneumococcal vacci-
nation has improved over the years,8 use was low in 1989
when participants were enrolled in the CHS. Octogenarians
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pronounced among those with prior pneumococcal vaccina-
tion. However, despite accumulation of higher proportion of
susceptible patients, we observed a lower risk of incident
HF and cardiovascular events among these patients. It is pos-
sible that some of the octogenarians in the unvaccinated
group were vaccinated during follow-up or that recollection
of vaccination was inaccurate resulting in incorrect classifica-
tion. However, this would be expected to result in regression
dilution and underestimation of the true association.33 Fi-
nally, because findings of our study are hypothesis-generating
and do not provide mechanistic insights, they need to be
interpreted with caution.
Conclusions
Among community-dwelling octogenarians, lack of pneumo-
coccal vaccination was associated with higher risk for incident
HF and CV mortality, with a trend toward higher risk for hos-
pitalization due to pneumonia. However, none of these asso-
ciations were observed among those 65–79 years of age. If
these hypothesis-generating findings can be replicated in
other octogenarian populations, it may provide a tool to
lower the risk of HF among octogenarians, the fastest
growing segment of the population in developing nations
who also has the highest risk of HF.
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